Idiopaty Trombositopeny Purpura

Sri Meutia; Ummi Issayyidah

doi:10.29103/jkkmm.v4i1.16610

Idiopaty Trombositopeny Purpura

Sri Meutia, Ummi Issayyidah

Abstract

Immune thrombocytopenia adalah penyakit autoimun yang ditandai dengan jumlah trombosit rendah dan meningkatnya risiko perdarahan. Jumlah trombosit rendah dapat disebabkan oleh proses penghancuran trombosit yang dimediasi oleh sistem antibodi bersamaan dengan gangguan produksi trombosit, sehingga ITP tidak dapat lagi dianggap sebagai penyakit idiopatik. ITP dapat menyerang siapa saja tanpa memandang jenis kelamin, ras, dan usia. Dari analisis data Maryland Health Care Commission, prevalensi ITP di Amerika Serikat adalah 9,5 kasus per 100.000 anak usia 1–5 tahun, 7,3 kasus per 100.000 anak pada usia 6 – 10 tahun, dan 4,1 kasus per 100.000 anak usia 11 – 14 tahun, sementara di Eropa Utara insidens tahunan mencapai 2,68 kasus per 100.000 orang. Gejala dan tanda klinis yang menunjukkan trombositopenia dapat ditemui secara umum pada perawatan primer. Tanda-tanda trombositopenia seperti petechia dan purpura adalah presentasi umum untuk perawatan primer. ITP dapat diklasifikasikan menjadi newly diagnose, ITP persisten dan ITP kronik.

Keywords

Immune thrombocytpenia, trombositopenia, petechia dan purpura

Full Text:

PDF

References

Ma I, Sandhu At. Immune Thrombocytopenia. Hosp Med Clin. 2017;6(1):53-66.

Sadaq A. Kadar Imunoglobulin-G (Igg) Anti-Hpa Dengan Metode Enzym Linked Immunosorbant Assay (Elisa) Pada Pasien Immune Thrombocytopeniadi Rumah Sakit Wahidin Sudirohusodo Makassar. 2021.

Neunert C, Vesely Sk, Mithoowani S, Kim T. Management Of Immune Thrombocytopenia (Itp). Am Soc Hematol. 2021;(November):1–5.

Bailey Lc. Immune Thrombocytopenic Purpura. 5-Minute Pediatr Consult 8th Ed [Internet]. 2019;9(1):500–1. Available From: Https://Doi.Org/10.1080/20009666.2019.1565884.

Desouza S, Angelini D. Updated Guidelines For Immune Thrombocytopenic Purpura: Expanded Management Options. Cleve Clin J Med. 2021;88(12):664–8.

Park Yh, Kim Dy, Kim S, Choi Yb, Shin Dy, Kim Js, Et Al. Management Of Immune Thrombocytopenia: 2022 Update Of Korean Experts Recommendations. Blood Res. 2022;57(1):20–8.

Mishra S, Shridhar A, Prakash J. Standard Treatment Guidelines 2022. 2023.

Kistanguri G Mck. Immune Thrombocytopenia. Hematol Oncol Clin North Am. 2013;495-520.

Swinkels M, Rijkers M, Voorberg J, Vidarsson G, Leebeek F Ja. Emerging Concepts In Immune Thrombocytopenia. Front Immunol. 2018;9:880.

Lozano Ml, Godeau B, Grainger J, Matzdorff A, Rodeghiero F, Hippenmeyer J, Et Al. Romiplostim In Adults With Newly Diagnosed Or Persistent Immune Thrombocytopenia. Expert Rev Hematol [Internet]. 2020;13(12):1319–32.Available From:Https://Doi.Org/10.1080/17474086.2020.1850253

Neunert C, Lim W, Crowther Ma, Cohen A, Solberg L. The American Society Of Hematology 2011 Evidence-Based Practice Guideline For Immune Thrombocytopenia. Blood. 2011;117(16):4190–207.

Zitek T, Weber L, Pinzon D Wn. Assessment And Management Of Immune Thrombocytopenia (Itp) In The Emergency Department: Current Perspectives. Open Access Emerg Med. 2022;14:25–34.

Rafei H, Yunus R Ns. Post-Transfusion Purpura: A Case Report Of An Underdiagnosed Phenomenon. Pumed. 2017.

Hawkins J, Aster Rh Cb. Post-Transfusion Purpura: Current Perspectives. J Blood Med. 2019;10:405–15.

Torrez M, Chabot-Richards D, Babu D, Lockhart E Fk. How I Investigate Acquired Megaloblastic Anemia. Int J Lab Hematol. 2022;2(44):236–47.

Visweshwar N, Ayala I, Jaglal M, Killeen R, Sokol L, Laber Da Ma. Primer Immune Thrombocytopenia A ―Diagnosis Exclusion‖? Blood Coagul Fibrinolysis. 2022;6(33):289-294.

South East London Area Prescribing Committee. South East London Guideline For The Investigation And Management Of Immune Thrombocytopenia ( Itp ) In Adult Patients Over 18 Years Old. Nhs. 2022(July):1–13.

DOI: https://doi.org/10.29103/jkkmm.v4i1.16610